STOCKS | Bambusa Therapeutics Falls 7% on Debut After $168.9 Million IPO
CoinLive
Bambusa Therapeutics Inc. shares fell 7% in their trading debut after the early-stage biotech raised $168.9 million in a US initial public offering, Bloomberg reported. The company focuses on dermatology and autoimmune diseases.